Heron Therapeutics' (HRTX) Price Target Raised to $54 at BofA/Merrill Lynch
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Heron Therapeutics Reports Positive Top-Line Results from Phase 2 Study of HTX-011 in the Management of Post-Operative Pain
September 22, 2015 4:05 PM EDT
-Pain intensity through 24 hours reduced by 69%
-Pain
intensity through 72 hours reduced by 40%
-Time to first use
of opiate rescue medication increased by 488%
-32% of
patients received no opiate rescue through 72 hours compared to 5% for
placebo
Conference call and webcast at 8:30 am ET on September 23
REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Heron Therapeutics, Inc. (NASDAQ:... More
